Blood and plasma device supplier, Haemonics, has signed a deal to acquire all outstanding shares of the Canadian optical imaging company Opensens at a value of $253 million.
Haemonics has said that gaining the imaging firm will allow it to expand its cardiology offerings and add Opensens’ proprietary sensor-guided 3-in-1 guidewire, intended for use in Transcatheter Aortic Valve Replacement (TAVR) procedures, to its portfolio.
The Qubec-based OpenSens had previously developed the guidewire technology that acts as a pacing and pressure monitoring wire advancing the flow of the procedure and enabling potentially shorter hospital stays for patients.
Opensens’ portfolio also includes the OptoWire, a pressure guidewire that aims to improve clinical outcomes by measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease.
Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction set to be overseen and administered by the Quebec government.
Haemonics has also said that the acquisition of Opensens’ technology will allow it to strengthen its market presence by allowing it to enter more fully into interventional cardiology, a market the company claims to have an addressable market of approximately $1 billion.
Stewart Strong, president of Haemonetics, said: "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification.
“By leveraging OpSens' proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top US hospitals performing TAVR and PCI procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide. We are excited to welcome OpSens' talented team and look forward to advancing our shared commitment to maximizing patient benefits and value for our customers."
